Literature DB >> 3342468

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo.

T Tsuruo1, T Matsuzaki, M Matsushita, H Saito, T Yokokura.   

Abstract

CPT-11, a new derivative of camptothecin, was effective against tumor cells, especially vincristine (VCR)-and adriamycin (ADM)-resistant P388 leukemia, compared to either VCR or ADM. The drug showed superior chemotherapeutic effects over VCR and ADM in sensitive P388 leukemia-bearing mice, and was also effective in VCR- and ADM-resistant P388 leukemia-bearing mice. These latter survival advantages with CPT-11 were almost equal to those obtained by CPT-11 against sensitive P388 leukemia. CPT-11 was found to be effective against human tumor cells, especially various pleiotropically drug-resistant human tumor lines, compared to VCR and ADM. CPT-11 should be considered for further development as a new chemotherapeutic agent potentially effective against pleiotropically drug-resistant tumors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3342468     DOI: 10.1007/bf00262744

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  19 in total

1.  Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones.

Authors:  T Tsuruo; H Iida-Saito; H Kawabata; T Oh-hara; H Hamada; T Utakoji
Journal:  Jpn J Cancer Res       Date:  1986-07

2.  Characteristics of vincristine resistance in vincristine resistant human myelogenous leukemia K562.

Authors:  T Tsuruo; T Oh-Hara; H Saito
Journal:  Anticancer Res       Date:  1986 Jul-Aug       Impact factor: 2.480

3.  Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells.

Authors:  K Dano
Journal:  Biochim Biophys Acta       Date:  1973-10-25

4.  Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.

Authors:  P J Creaven; L M Allen; F M Muggia
Journal:  Cancer Chemother Rep       Date:  1972-10

5.  Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts.

Authors:  W T Beck; T J Mueller; L R Tanzer
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

6.  Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.

Authors:  T Tsuruo; H Iida; M Nojiri; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

7.  Comparison of cytotoxic effect and cellular uptake of 1-beta-D-arabinofuranosylcytosine and its N4-acyl derivatives, using cultured KB cells.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

8.  Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.

Authors:  T Andoh; K Ishii; Y Suzuki; Y Ikegami; Y Kusunoki; Y Takemoto; K Okada
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

9.  Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.

Authors:  M Inaba; H Kobayashi; Y Sakurai; R K Johnson
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

10.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

Authors:  Y H Hsiang; R Hertzberg; S Hecht; L F Liu
Journal:  J Biol Chem       Date:  1985-11-25       Impact factor: 5.157

View more
  36 in total

Review 1.  Clinical pharmacokinetics of irinotecan.

Authors:  G G Chabot
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

Review 2.  Topoisomerases, new targets in cancer chemotherapy.

Authors:  J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

Review 3.  Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.

Authors:  L R Wiseman; A Markham
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 4.  Topoisomerase I in multiple drug resistance.

Authors:  A Pessina
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

5.  In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors.

Authors:  A Kojima; N R Hackett; A Ohwada; R G Crystal
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

Review 6.  Topoisomerase inhibitors. A review of their therapeutic potential in cancer.

Authors:  B K Sinha
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

7.  Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.

Authors:  G G Chabot
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 8.  Camptothecins: a review of their chemotherapeutic potential.

Authors:  Hulya Ulukan; Peter W Swaan
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.

Authors:  Y Kawato; T Furuta; M Aonuma; M Yasuoka; T Yokokura; K Matsumoto
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 10.  New strategy for overcoming resistance to chemotherapy of ovarian cancer.

Authors:  Junzo Kigawa
Journal:  Yonago Acta Med       Date:  2013-07-12       Impact factor: 1.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.